title: Cancer drug development in China: recent advances and future challenges.
abstract: Over the past 10 years, the Chinese Government, academic organizations, and biopharmaceutical companies have tried to transition the nation from a consumer of generic drugs into a developer of innovative therapies. Here, we present a timeline of recent innovative cancer drug development, with a particular focus on four case studies that have reshaped perceptions of what can be done in China. We present metrics comparing China with other countries alongside analysis of what national authorities are doing to close the gap in areas where China still lags behind the West.
authors.affiliation: Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: syylwu@live.cn.
authors.forename: Yi-Long
authors.initials: YL
authors.lastname: Wu
authors.affiliation: Quintiles China, Shanghai 200032, China.
authors.forename: Helena
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Quintiles China, Beijing 100006, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Yang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D002681:China / Q000453:epidemiology; D004059:Diffusion of Innovation; D055808:Drug Discovery / Q000639:trends*; D005544:Forecasting; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D058990:Molecular Targeted Therapy / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents